

Recombinant Protein Technical Manual Recombinant Rat PDGFRa/CD140a Protein (Fc Tag) RPES3519

Product Data:

Product SKU: RPES3519	Size: 50µg
Species: Rat	Expression host: HEK293 Cells

Uniprot: G3V6A0

Protein Information:		
Molecular Mass:	83.2 kDa	
AP Molecular Mass:	11220 kDa	
Tag:	C-Fc	
Bio-activity:		
Purity:	(96.6+2.8) % as determined by SDS-PAGE	
Endotoxin:	< 1.0 EU per μg of the protein as determined by the LAL method	
Storage:	Lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.	
Shipping:	This product is provided as lyophilized powder which is shipped with ice packs.	
Formulation:	Lyophilized from sterile PBS, pH 7.4	
Reconstitution:	Please refer to the printed manual for detailed information.	
Application:		
Synonyms:	PDGFRA	

Sequence: Met1-Glu523

Background:

PDGFRA, also known as CD140a, together with the structurally homolog protein PDGFRB (CD140b), are cell surface receptors for members of the platelet-derived growth factor family. They are members of the class III subfamily of receptor tyrosine kinase (RTKs) with the similar structure characteristics of five immunoglobulin-like domains in their extracellular region and a split kinase domain in their intracellular region. PDGFRA is expressed in oligodendrocyte progenitor cells and mesothelial cell, and binds all three ligand isoforms PDGF-AA, PDGF-BB and PDGF-AB with high affinity, whereas PDGFRB dose not bind PDGF-AA. PDGFRA plays an essential role in regulating proliferation, chemotaxis and migration of mesangial cells. Recent studies have indicated that PDGFRA acts as a critical mediator of signaling in testis organogenesis and Leydig cell differentiation, and in addition, particularly important for kidney development. Additionally, PDGFRA is involved in tumor angiogenesis and maintenance of the tumor microenvironment and has been implicated in development and metastasis of Hepatocellular carcinoma (HCC). PDGFRA may represent a potential therapeutic target in thymic tumours. PDGFRA gene amplification rather than gene mutation may be the underlying genetic mechanism driving PDGFRA overexpression in a portion of gliomas.